- According to a report by the IQVIA Institute for Human Data Science, more than 80,000 diagnoses of 5 common cancers in the United States may be missed or delayed by early June 2020 as a result of COVID-19-related health care disruptions.
Why this matters
- The COVID-19 pandemic has affected the entire US health care system, including cancer care, directly and indirectly.
- Analysis of data from IQVIA’s medical claims database, which includes >205 million patients, >1.7 billion claims, and 3 billion service records obtained annually.
- Funding: No external funding from industry or government.
- Rates of screening and monitoring for breast, prostate, colorectal, cervical, and lung cancer had declined by 39%-90% in early April compared with February (baseline month).
- At current positivity rates, estimates for missed or delayed cancer diagnoses from early March through early June are as follows:
- Breast: 36,000;
- Lung: 450;
- Cervical: 2500;
- Colorectal: 18,800; and
- Prostate: 22,600.
- 22 million tests for the 5 cancers are expected to be canceled or delayed during the 3-month period.
- Claims data often have limited clinical information.